Pharminent

GSK/J&J release how their drug measures up against Humira

GlaxoSmithKline and Janssen, part of Johnson & Johnson, released the results of their two Phase III trials exploring treatment options for adults suffering from active rheumatoid arthritis, in comparison with market leader Humira. The trial evaluated the drug sirukumab, co-developed by the two companies, which is a human anti-interleukin (IL)-6 monoclonal antibody.
read more http://www.pharmafile.com/news/511433/gskjj-release-how-their-drug-measure-against-humira

Filed under: Arthritis